Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

ClinicalTrials.gov ID: NCT05263999

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05263999. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids

Study identification

NCT ID
NCT05263999
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Equillium
Industry
Enrollment
158 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2022 (Actual)
Primary completion
Apr 22, 2025 (Actual)
Completion
May 12, 2025 (Actual)
Last update posted
Jun 17, 2025

2022 – 2025

United States locations

U.S. sites
38
U.S. states
20
U.S. cities
34
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294 —
City of Hope Duarte California 91010 —
University of California, San Diego (UCSD) - Moores Cancer Center La Jolla California 92093 —
University of Southern California Los Angeles California 90033 —
University of California, Los Angeles (UCLA) - Medical Center Los Angeles California 90059 —
Stanford Cancer Center Stanford California 94305 —
AdventHealth Orlando Orlando Florida 32804 —
Moffitt Cancer Center Tampa Florida 33612 —
Emory University Atlanta Georgia 30322 —
Northwestern Memorial Hospital Chicago Illinois 60611 —
The University of Chicago Medical Center (UCMC) Chicago Illinois 60637 —
Loyola University Chicago, performing research at Loyola University Medical Center Maywood Illinois 60153 —
University of Iowa Iowa City Iowa 52242 —
Tulane University Medical Center New Orleans Louisiana 70112 —
University of Maryland Medical Center Baltimore Maryland 21201 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 —
Dana-Farber Cancer Institute Boston Massachusetts 02215 —
University of Michigan Ann Arbor Michigan 48109 —
Henry Ford Hospital Detroit Michigan 48202 —
Spectrum Health Grand Rapids Michigan 49503 —
Mayo Clinic - Rochester Rochester Minnesota 55905 —
John Theurer Cancer Center At Hackensack UMC Hackensack New Jersey 07601 —
Rutgers Cancer Institute of NJ New Brunswick New Jersey 08901 —
Northwell Health Lake Success New York 11042 —
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center New York New York 10065 —
Stony Brook University Medical Center Stony Brook New York 11794 —
University of North Carolina (UNC) Chapel Hill North Carolina 27514 —
Wake Forest Winston-Salem North Carolina 27157 —
Oncology Hematology in Cincinnati Cincinnati Ohio 45242 —
University Hospitals Cleveland Medical Center Cleveland Ohio 44106 —
The Ohio State University (OSU) Columbus Ohio 43201 —
Oregon Health & Science University (OHSU) Portland Oregon 97239 —
University of Pennsylvania Abramson Cancer Center Philadelphia Pennsylvania 19104 —
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Pittsburgh Pennsylvania 15232 —
Sarah Cannon Research Institute, LLC (SCRI) Nashville Tennessee 37203 —
Baylor Scott & White Research Institute Dallas Texas 75246 —
UT Southwestern Medical Center Dallas Texas 75390 —
Fred Hutchinson Cancer Research Center Seattle Washington 98109 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05263999, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 17, 2025 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.